StockNews.com Initiates Coverage on Trevena (NASDAQ:TRVN)

StockNews.com assumed coverage on shares of Trevena (NASDAQ:TRVN) in a research report report published on Sunday morning. The firm issued a sell rating on the biopharmaceutical company’s stock.

Separately, HC Wainwright reissued a “neutral” rating and issued a $5.00 price target on shares of Trevena in a research note on Thursday, November 14th.

Trevena Trading Down 1.8 %

Shares of NASDAQ TRVN opened at $1.64 on Friday. The business has a 50-day moving average of $1.73 and a 200-day moving average of $2.50. The firm has a market capitalization of $1.42 million, a price-to-earnings ratio of -0.03 and a beta of 1.08. Trevena has a 12 month low of $1.13 and a 12 month high of $17.50.

About Trevena

Trevena, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel medicines for patients affected by central nervous system disorders. Its lead product candidates include OLINVYK (Oliceridine) injection, a G protein biased mu-opioid receptor (MOR) ligand for the management of moderate-to-severe acute pain; TRV250, a G protein biased delta-opioid receptor agonist for the treatment of acute migraine; TRV734, a small molecule G protein biased ligand of the MOR for the treatment of moderate-to-severe acute and chronic pain; and TRV045, a novel S1P modulator for managing chronic pain.